Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251066 | 0.85 | HCAR2 (0.32) | HCAR2CYP11B2CYP11B1 | |
| SCHEMBL22452947 | 0.84 | HCAR2 (0.34) | HCAR2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL19139344 | 0.82 | CNR2 (0.38) | — | |
| SCHEMBL20993134 | 0.80 | CYP11B2 (0.36) | CYP11B2CYP11B1 | |
| SCHEMBL19274406 | 0.79 | GABRA1 (0.34) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL22752310 | 0.79 | CNR2 (0.45) | — | |
| SCHEMBL19251067 | 0.79 | CNR2 (0.45) | — | |
| SCHEMBL6371572 | 0.79 | HCAR2 (0.39) | HCAR2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL19251180 | 0.78 | HCAR2 (0.31) | HCAR2CYP11B2CYP11B1 | |
| SCHEMBL12525141 | 0.78 | HCAR2 (0.35) | HCAR2CYP11B2CYP11B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | HCAR2 4275/4885CYP11B2 4231/4885CYP11B1 3834/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | HCAR2 1889/4885CYP11B2 1/4885CYP11B1 3/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | HCAR2 279/4885CYP11B2 59/4885CYP11B1 42/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | HCAR2 3804/4885CYP11B2 450/4885CYP11B1 313/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | HCAR2 3904/4885CYP11B2 396/4885CYP11B1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.